Ergothioneine Biosynthesis in Engineered E. coli
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for microbial ergothioneine biosynthesis are inefficient, with only three genes identified for ergothioneine production in vitro, and attempts to engineer the mycobacterial pathway in E. coli have been unsuccessful, resulting in low yields unsuitable for commercial production.
Innovation Solution
Engineered host cells transformed with nucleic acid sequences encoding EgtB, EgtC, EgtD, and EgtE are used to produce ergothioneine, allowing for the expression and collection of the compound, with suitable substrates and cofactors added to enhance production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If only three genes (EgtB, EgtC, EgtD) are used for ergothioneine production in vitro, then the biosynthesis pathway is simplified, but the production yield is too low to be commercially viable
Solution Approach 1:
The patent divides the ergothioneine biosynthesis pathway into discrete enzymatic steps, each catalyzed by a specific gene product (EgtB, EgtC, EgtD, EgtE). By segmenting the pathway and expressing each enzyme separately in E. coli, the system achieves both pathway simplicity and high yield through modular genetic construction and optimized expression of individual biosynthetic steps.
2Adaptability or versatility
If mycobacterial ergothioneine pathway is engineered in E. coli using available genes, then microbial production is achieved, but the yield remains insufficient for commercial production
Solution Approach 1:
The patent optimizes multiple parameters including gene expression levels, enzyme activity, substrate availability, and cultivation conditions to maximize ergothioneine yield in E. coli. By adjusting these parameters and identifying the critical EgtE enzyme, the system transforms the pathway from research-stage to commercially viable production.
Solution Approach 2:
The patent introduces EgtE as a missing intermediary enzyme that completes the ergothioneine biosynthesis pathway in E. coli. This intermediary component bridges the gap between available genetic resources and functional pathway reconstruction, enabling full pathway operation and high-yield production.
3Reliability
If fungal and mycobacterial sources are used for ergothioneine extraction, then natural production is maintained, but the yield is too low for industrial production
Solution Approach 1:
Instead of extracting ergothioneine from natural sources (fungi and mycobacteria), the patent copies the entire biosynthesis pathway into E. coli. This copying approach allows the system to reproduce natural ergothioneine production authentically while achieving high yields suitable for industrial production, avoiding the limitations of extraction from low-yield natural sources.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered host cells successfully produce ergothioneine, with significant yields achieved, demonstrating a viable method for commercial production by reproducing the ergothioneine production pathway in an in vitro microbial system.
Implementation Method 1
inducing the host cell to express the nucleic acid sequence encoding EgtB, the nucleic acid sequence encoding EgtC, the nucleic acid sequence encoding EgtD and the nucleic acid sequence encoding EgtE
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
Disclosed are methods for ergothioneine biosynthesis. More particularly, the present disclosure relates to methods for microbial ergothioneine biosynthesis. The present disclosure relates generally to engineered host cells and methods for producing ergothioneine. More particularly, the present disclosure relates to an engineered host cell and methods for microbial ergothioneine biosynthesis using the engineered host cell.